Speaking to the US market specifically, this was completely to be expected. It's literally happened for every one of their new product roll-outs (Elise, Exige, Evora, etc.). The few "I have to have it now..." pay a premium over MSRP (and in the Emira's case also waited 2+ years), only to have...